MCID: BRS044
MIFTS: 58

Breast Adenocarcinoma malady

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Breast Adenocarcinoma

Aliases & Descriptions for Breast Adenocarcinoma:

Name: Breast Adenocarcinoma 12 14 69
Adenocarcinoma of Breast 12 29
Mammary Adenocarcinoma 12 69

Classifications:



External Ids:

Disease Ontology 12 DOID:3458
NCIt 47 C5214
UMLS 69 C0858252

Summaries for Breast Adenocarcinoma

Disease Ontology : 12 A breast carcinoma that originates in the milk ducts and/or lobules (glandular tissue) of the breast.

MalaCards based summary : Breast Adenocarcinoma, also known as adenocarcinoma of breast, is related to colorectal cancer and adenocarcinoma. An important gene associated with Breast Adenocarcinoma is BAX (BCL2 Associated X, Apoptosis Regulator), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Capecitabine and Vinblastine have been mentioned in the context of this disorder. Affiliated tissues include breast, brain and colon, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and growth/size/body region

Related Diseases for Breast Adenocarcinoma

Diseases in the Breast Adenocarcinoma family:

Rare Adenocarcinoma of the Breast

Diseases related to Breast Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 124)
id Related Disease Score Top Affiliating Genes
1 colorectal cancer 27.1 BAX CASP7 CASP8 CDKN1A CYCS EGF
2 adenocarcinoma 10.7
3 achondrogenesis 10.3 EGF ERBB2
4 bladder clear cell adenocarcinoma 10.3 ESR1 TP53
5 glioma 10.3 ERBB2 ESR1
6 pineal region mature teratoma 10.3 EGFR ERBB2
7 central nervous system mature teratoma 10.3 ERBB2 ESR1 TP53
8 postpartum depression 10.3 ERBB2 ESR1 TP53
9 wolffian adnexal neoplasm 10.3 EGFR TP53
10 male reproductive organ benign neoplasm 10.3 ERBB2 ESR1 TP53
11 central nervous system primitive neuroectodermal neoplasm 10.3 ERBB2 ESR1 TP53
12 arthus reaction 10.3 ERBB2 ESR1 TP53
13 fallopian tube carcinosarcoma 10.3 ERBB2 ESR1 TP53
14 vulva adenocarcinoma 10.2 ERBB2 ESR1 TP53
15 her2-receptor positive breast cancer 10.2 EGF ERBB2 ESR1
16 cervical lymphoepithelioma-like carcinoma 10.2 EGFR ERBB2 ESR1
17 malignant giant cell tumor 10.2 MMP9 TNFSF11 TP53
18 nervous system hibernoma 10.2 EGFR ERBB2 ESR1
19 reactive arthritis 10.2 EGFR ERBB2 TP53
20 congenital bile acid synthesis defect 10.2 ERBB2 ESR1 TP53
21 spastic hemiplegia 10.2 EGF MMP9 TNFSF11
22 metagonimiasis 10.2 ERBB2 ESR1 TP53
23 spastic diplegia infantile type 10.2 BAX EGFR ERBB2
24 combined t cell and b cell immunodeficiency 10.2 EGFR ERBB2 ESR1
25 anomalous left coronary artery from the pulmonary artery 10.2 EGFR ERBB2 ESR1
26 immunodeficiency due to a late component of complement deficiency 10.2 EGFR ERBB2 TP53
27 anus adenocarcinoma 10.2 EGFR ERBB2 ESR1
28 sclerosing hemangioma 10.2 EGFR ERBB2 ESR1
29 gallbladder papillomatosis 10.2 BAX CDKN1A TP53
30 retinal disease 10.2 EGFR ERBB2 ESR1
31 statin toxicity 10.2 MMP9 TNFSF11 TP53
32 progesterone-receptor negative breast cancer 10.2 ERBB2 ESR1 TP53
33 organ system benign neoplasm 10.2 ERBB2 ESR1 PARP1
34 familial glucocorticoid deficiency 10.2 CASP8 ERBB2 ESR1 TP53
35 his bundle tachycardia 10.2 EGFR ERBB2 ESR1 TP53
36 estrogen-receptor positive breast cancer 10.2 EGFR ERBB2 ESR1 TP53
37 pyomyositis 10.2 EGFR ERBB2 ESR1 TP53
38 maxillary sinus cholesteatoma 10.2 CDKN1A MMP9 TP53
39 rete testis neoplasm 10.2 EGF PLAU
40 pulmonary fibrosis and/or bone marrow failure, telomere-related, 1 10.2 EGF EGFR ERBB2 TP53
41 dental caries 10.2 EGFR ERBB2 ESR1 TP53
42 nasal cavity disease 10.2 EGFR ERBB2 ESR1 TP53
43 prostatic adenoma 10.2 EGFR ERBB2 ESR1 TP53
44 pituitary stalk meningioma 10.2 ERBB2 ESR1 TP53
45 progesterone-receptor positive breast cancer 10.2 EGFR ERBB2 ESR1 TP53
46 breast malignant phyllodes tumor 10.2 EGFR ERBB2 ESR1 TP53
47 spastic paraplegia 1 10.1 EGFR TNF TP53
48 uvula cancer 10.1 BAX CASP8 EGFR ERBB2
49 acute mountain sickness 10.1 CDKN1A TNF TP53
50 fallopian tube adenocarcinoma 10.1 CDKN1A ERBB2 ESR1 TP53

Graphical network of the top 20 diseases related to Breast Adenocarcinoma:



Diseases related to Breast Adenocarcinoma

Symptoms & Phenotypes for Breast Adenocarcinoma

GenomeRNAi Phenotypes related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 ALDH3A1 BAX CASP7 CASP8 CDKN1A TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 ALDH3A1 BAX CASP7 CASP8 CDKN1A TNF

MGI Mouse Phenotypes related to Breast Adenocarcinoma:

44 (show all 25)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.52 ALDH3A1 BAX CASP8 CDKN1A CTSK CYCS
2 cellular MP:0005384 10.51 BAX CASP7 CASP8 CDKN1A CTSK CYCS
3 endocrine/exocrine gland MP:0005379 10.45 ESR1 FOS PLAU TNF TNFSF11 TP53
4 hematopoietic system MP:0005397 10.45 BAX CASP7 CASP8 CDKN1A CTSK CYCS
5 immune system MP:0005387 10.45 TNFSF11 TP53 BAX CASP7 CASP8 CDKN1A
6 homeostasis/metabolism MP:0005376 10.41 BAX CASP8 CDKN1A CTSK EGFR ERBB2
7 behavior/neurological MP:0005386 10.4 CYCS ERBB2 ESR1 FOS MMP9 PARP1
8 cardiovascular system MP:0005385 10.35 CASP7 CASP8 CDKN1A CYCS EGFR ERBB2
9 mortality/aging MP:0010768 10.33 BAX CASP7 CASP8 CDKN1A CYCS EGFR
10 integument MP:0010771 10.32 TNF TNFSF11 TP53 CASP8 CDKN1A EGF
11 craniofacial MP:0005382 10.3 CDKN1A CTSK CYCS EGFR ERBB2 FOS
12 digestive/alimentary MP:0005381 10.29 CDKN1A CTSK EGF EGFR ERBB2 ESR1
13 embryo MP:0005380 10.28 CASP8 CDKN1A CYCS EGFR ERBB2 ESR1
14 limbs/digits/tail MP:0005371 10.24 BAX CDKN1A CTSK EGFR ERBB2 ESR1
15 nervous system MP:0003631 10.24 BAX CASP7 CASP8 CDKN1A CTSK CYCS
16 adipose tissue MP:0005375 10.22 CDKN1A CTSK EGFR ESR1 NQO1 PLAU
17 neoplasm MP:0002006 10.22 BAX CASP8 CDKN1A EGFR ERBB2 ESR1
18 muscle MP:0005369 10.17 BAX CASP8 CDKN1A EGFR ERBB2 ESR1
19 hearing/vestibular/ear MP:0005377 10.1 BAX CDKN1A EGFR FOS PARP1 PLAU
20 liver/biliary system MP:0005370 10.08 CASP8 CDKN1A EGFR ESR1 NQO1 PLAU
21 reproductive system MP:0005389 10.07 BAX CDKN1A EGF EGFR ERBB2 ESR1
22 respiratory system MP:0005388 9.93 BAX CASP8 CDKN1A CTSK EGFR ERBB2
23 renal/urinary system MP:0005367 9.92 BAX CASP8 CDKN1A EGFR ESR1 MMP9
24 skeleton MP:0005390 9.8 ERBB2 ESR1 FOS MMP9 PLAU TNF
25 vision/eye MP:0005391 9.36 FOS MMP9 PLAU TNF TNFSF11 TP53

Drugs & Therapeutics for Breast Adenocarcinoma

Drugs for Breast Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 388)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
2
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
3
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
4
Tamoxifen Approved Phase 3,Phase 2 10540-29-1 2733526
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
6
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
7
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
8
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
9
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
10
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
11
Carboplatin Approved Phase 2, Phase 3, Phase 1 41575-94-4 10339178 498142 38904
12
Trastuzumab Approved, Investigational Phase 2, Phase 3, Phase 1 180288-69-1 9903
13
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
14
Sunitinib Approved, Investigational Phase 3,Phase 2 341031-54-7, 557795-19-4 5329102
15
Pancrelipase Approved Phase 3,Phase 2,Phase 1 53608-75-6
16
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-28-2 5757 53477783
17
Fulvestrant Approved, Investigational Phase 3,Phase 2,Phase 1 129453-61-8 104741 17756771
18
Progesterone Approved, Vet_approved Phase 3,Phase 1,Phase 2,Early Phase 1 57-83-0 5994
19
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
20
Everolimus Approved Phase 3,Phase 1,Phase 2 159351-69-6 6442177
21
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 22916-47-8 4189
22
Sirolimus Approved, Investigational Phase 3,Phase 1,Phase 2 53123-88-9 5284616 6436030 46835353
23
Letrozole Approved, Investigational Phase 3,Phase 2,Phase 1 112809-51-5 3902
24
Levoleucovorin Approved Phase 3,Phase 2,Phase 1 68538-85-2
25
Anastrozole Approved, Investigational Phase 3,Phase 2 120511-73-1 2187
26
Doxorubicin Approved, Investigational Phase 2, Phase 3, Phase 1 23214-92-8 31703
27
Cetuximab Approved Phase 3,Phase 1,Phase 2 205923-56-4 56842117 2333
28
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
29
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
30
lanreotide Approved Phase 2, Phase 3 108736-35-2
31
Octreotide Approved, Investigational Phase 2, Phase 3, Phase 1 83150-76-9 383414 6400441
32
Somatostatin Approved Phase 2, Phase 3,Phase 1 38916-34-6, 51110-01-1 53481605
33
Sorafenib Approved, Investigational Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
34
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
35
Cisplatin Approved Phase 2, Phase 3, Phase 1 15663-27-1 84093 441203 2767
36
Zoledronic acid Approved Phase 2, Phase 3 118072-93-8 68740
37
Metformin Approved Phase 3,Phase 2,Phase 1 657-24-9 14219 4091
38
Denosumab Approved Phase 3,Phase 2 615258-40-7
39
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
40
Goserelin Approved Phase 2, Phase 3 65807-02-5 47725 5311128
41
Leuprolide Approved, Investigational Phase 2, Phase 3 53714-56-0 3911 657181
42
Pertuzumab Approved Phase 3,Phase 2,Phase 1 145040-37-5, 380610-27-5 2540
43
Celecoxib Approved, Investigational Phase 2, Phase 3 169590-42-5 2662
44
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
45
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
46
Exemestane Approved, Investigational Phase 3,Phase 2,Phase 1 107868-30-4 60198
47
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
48
Trametinib Approved Phase 2, Phase 3,Phase 1 871700-17-3 11707110
49
Succinylcholine Approved Phase 3,Phase 2,Phase 1 306-40-1 5314
50
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634

Interventional clinical trials:

(show top 50) (show all 499)
id Name Status NCT ID Phase
1 Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET Completed NCT00904410 Phase 4
2 Study of Autologous Fat Enhanced w/ Regenerative Cells Transplanted to Reconstruct Breast Deformities After Lumpectomy Completed NCT00616135 Phase 4
3 Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer Completed NCT00742222 Phase 4
4 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Completed NCT01448447 Phase 4
5 Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC) Unknown status NCT01126138 Phase 3
6 Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer Completed NCT00949598 Phase 3
7 Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer Completed NCT00140075 Phase 3
8 Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer Completed NCT00096278 Phase 3
9 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3
10 Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis Completed NCT00243685 Phase 2, Phase 3
11 Conservative Surgery With or Without Axillary Lymphnode Removal in Treating Women With T1N0 Breast Cancer Completed NCT01508546 Phase 3
12 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
13 Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3
14 Intraoperative Gamma Camera for Breast Cancer Surgery Completed NCT00757302 Phase 3
15 Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer Completed NCT00079274 Phase 3
16 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3
17 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
18 S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Completed NCT00134056 Phase 3
19 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
20 GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma Completed NCT00495846 Phase 2, Phase 3
21 Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery Completed NCT00326898 Phase 3
22 Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Recruiting NCT02488967 Phase 3
23 Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer Recruiting NCT01916317 Phase 3
24 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery Recruiting NCT01013649 Phase 3
25 Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1 Recruiting NCT02620280 Phase 3
26 Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients Recruiting NCT02221999 Phase 2, Phase 3
27 A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) Recruiting NCT02125344 Phase 3
28 Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response to Neoadjuvant Chemotherapy Recruiting NCT02879513 Phase 3
29 STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial Recruiting NCT00268476 Phase 2, Phase 3
30 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Recruiting NCT01272037 Phase 3
31 Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery Recruiting NCT01953588 Phase 3
32 Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer Recruiting NCT01905046 Phase 3
33 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Recruiting NCT02101788 Phase 2, Phase 3
34 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT00565851 Phase 3
35 Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery Recruiting NCT01101451 Phase 3
36 Oxybutynin Chloride in Managing Hot Flashes Recruiting NCT02961790 Phase 3
37 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Recruiting NCT02065687 Phase 2, Phase 3
38 Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Recruiting NCT01575548 Phase 3
39 A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC Recruiting NCT02627963 Phase 3
40 Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer Active, not recruiting NCT00005970 Phase 3
41 Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Active, not recruiting NCT00310180 Phase 3
42 Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement Active, not recruiting NCT00869206 Phase 3
43 Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing Coordinator Active, not recruiting NCT00321048 Phase 3
44 Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy Active, not recruiting NCT00556374 Phase 3
45 A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Active, not recruiting NCT00887536 Phase 3
46 Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Active, not recruiting NCT01196390 Phase 3
47 Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) Active, not recruiting NCT01583426 Phase 3
48 Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast Active, not recruiting NCT00470236 Phase 3
49 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Active, not recruiting NCT00769379 Phase 3
50 Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Active, not recruiting NCT00265850 Phase 3

Search NIH Clinical Center for Breast Adenocarcinoma

Genetic Tests for Breast Adenocarcinoma

Genetic tests related to Breast Adenocarcinoma:

id Genetic test Affiliating Genes
1 Breast Adenocarcinoma 29

Anatomical Context for Breast Adenocarcinoma

MalaCards organs/tissues related to Breast Adenocarcinoma:

39
Breast, Brain, Colon, Liver, Endothelial, Bone, Prostate

Publications for Breast Adenocarcinoma

Articles related to Breast Adenocarcinoma:

(show top 50) (show all 298)
id Title Authors Year
1
Therapeutic effects of bach1 siRNA on human breast adenocarcinoma cell line. ( 28092843 )
2017
2
Fas-associated protein with death domain (FADD) regulates autophagy through promoting the expression of Ras homolog enriched in brain (Rheb) in human breast adenocarcinoma cells. ( 27013580 )
2016
3
In vitro cytotoxic effect of tyrosine kinase inhibitor sunitinib malate alone and in combination with hyperthermia on breast adenocarcinoma MCF-7 cells. ( 27569072 )
2016
4
Ultrastructural Assessment of 2-(acridin-9-ylmethylene)-N-phenylhydrazinecarbothioamide activity on human breast adenocarcinoma cells. ( 27668344 )
2016
5
Correction for Upadhyay et al., Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain. ( 26884179 )
2016
6
Cytotoxicity of Manganese (III) Complex in Human Breast Adenocarcinoma Cell Line Is Mediated by the Generation of Reactive Oxygen Species Followed by Mitochondrial Damage. ( 27461214 )
2016
7
HMGI-C suppressing induces P53/caspase9 axis to regulate apoptosis in breast adenocarcinoma cells. ( 27245202 )
2016
8
Aldehyde dehydrogenase 3A1 promotes multi-modality resistance and alters gene expression profile in human breast adenocarcinoma MCF-7 cells. ( 27276244 )
2016
9
Silencing of High Mobility Group Isoform I-C (HMGI-C) Enhances Paclitaxel Chemosensitivity in Breast Adenocarcinoma Cells (MDA-MB-468). ( 27478778 )
2016
10
Synthesis of polydopamine as a new and biocompatible coating of magnetic nanoparticles for delivery of doxorubicin in mouse breast adenocarcinoma. ( 27752764 )
2016
11
Phyto-synthesis of silver nanoparticles using Alternanthera tenella leaf extract: an effective inhibitor for the migration of human breast adenocarcinoma (MCF-7) cells. ( 26801668 )
2016
12
Cambogin exerts anti-proliferative and pro-apoptotic effects on breast adenocarcinoma through the induction of NADPH oxidase 1 and the alteration of mitochondrial morphology and dynamics. ( 27418140 )
2016
13
Inhibition of mouse breast adenocarcinoma growth by ablation with intratumoral alpha-irradiation combined with inhibitors of immunosuppression and CpG. ( 27495172 )
2016
14
A Bowman-Birk inhibitor induces apoptosis in human breast adenocarcinoma through mitochondrial impairment and oxidative damage following proteasome 20S inhibition. ( 27551492 )
2016
15
Inhibitory and Cytotoxic Activities of Chrysin on Human Breast Adenocarcinoma Cells by Induction of Apoptosis. ( 27761071 )
2016
16
184AA3: a xenograft model of ER+ breast adenocarcinoma. ( 26661596 )
2016
17
Mitochondrial thiol modification by a targeted electrophile inhibits metabolism in breast adenocarcinoma cells by inhibiting enzyme activity and protein levels. ( 26774751 )
2016
18
The application of the linear quadratic model to compensate the effects of prolonged fraction delivery time on a Balb/C breast adenocarcinoma tumor: An in vivo study. ( 26630280 )
2016
19
Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions:: A Cell-Block Microarray Study. ( 27338760 )
2016
20
Microbial-catalysed derivatization of anti-cancer drug exemestane and cytotoxicity of resulting metabolites against human breast adenocarcinoma cell line (MCF-7) in vitro. ( 27521799 )
2016
21
Ajwa Date (Phoenix dactylifera L.) Extract Inhibits Human Breast Adenocarcinoma (MCF7) Cells In Vitro by Inducing Apoptosis and Cell Cycle Arrest. ( 27441372 )
2016
22
Role of Glutathione System Redox Potential in Apoptosis Dysregulation in MCF-7 Breast Adenocarcinoma. ( 26750929 )
2016
23
SERS-active Au/SiO2 clouds in powder for rapid ex vivo breast adenocarcinoma diagnosis. ( 27375955 )
2016
24
Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: In vitro and in vivo evaluation. ( 26802496 )
2016
25
Anticancer Activity of Curcumin on Human Breast Adenocarcinoma: Role of Mcl-1 Gene. ( 26413251 )
2015
26
The comparison of anticancer activity of thymoquinone and nanothymoquinone on human breast adenocarcinoma. ( 25901162 )
2015
27
Sonochemotherapy of breast adenocarcinoma: an experimental in vivo model. ( 26191104 )
2015
28
Cerebrospinal fluid cell cannibalism in metastatic breast adenocarcinoma. ( 26017217 )
2015
29
Enhanced cytotoxicity in triple-negative and estrogen receptora89positive breast adenocarcinoma cells due to inhibition of the transient receptor potential melastatin-2 channel. ( 26178079 )
2015
30
Epithelial cell adhesion molecule aptamer conjugated PEG-PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro. ( 25529433 )
2015
31
Evaluation of fractionated and repeated sonodynamic therapy by using dual frequency for murine model of breast adenocarcinoma. ( 26124951 )
2015
32
Apoptotic Effects of Two COX-2 Inhibitors on Breast Adenocarcinoma Cells Through COX-2 Independent Pathway. ( 25142612 )
2015
33
RSK4 knockdown promotes proliferation, migration and metastasis of human breast adenocarcinoma cells. ( 26397146 )
2015
34
Participation of non-neuronal muscarinic receptors in the effect of carbachol with paclitaxel on human breast adenocarcinoma cells. Roles of nitric oxide synthase and arginase. ( 25812766 )
2015
35
Targeting Cellular Metabolism Chemosensitizes the Doxorubicin-Resistant Human Breast Adenocarcinoma Cells. ( 26558272 )
2015
36
Human Mesenchymal Stromal Cells Transplantation May Enhance or Inhibit 4T1 Murine Breast Adenocarcinoma through Different Approaches. ( 26000020 )
2015
37
Oxidative modification induced by photodynamic therapy with PhotofrinArII and 2-methoxyestradiol in human ovarian clear carcinoma (OvBH-1) and human breast adenocarcinoma (MCF-7) cells. ( 25960212 )
2015
38
(6E,10E) Isopolycerasoidol and (6E,10E) Isopolycerasoidol Methyl Ester, Prenylated Benzopyran Derivatives from Pseuduvaria monticola Induce Mitochondrial-Mediated Apoptosis in Human Breast Adenocarcinoma Cells. ( 25946039 )
2015
39
Quercetin protects necrotic insult and promotes apoptosis by attenuating the expression of RAGE and its ligand HMGB1 in human breast adenocarcinoma cells. ( 25983116 )
2015
40
Internalization and Recycling of the HER2 Receptor on Human Breast Adenocarcinoma Cells Treated with Targeted Phototoxic Protein DARPinminiSOG. ( 26483969 )
2015
41
Effects of sulfated and non-sulfated I^-glucan extracted from Agaricus brasiliensis in breast adenocarcinoma cells - MCF-7. ( 25970150 )
2015
42
Breast adenocarcinoma recurring as small cell carcinoma in a patient with a germline BRCA2 mutation: clonal evolution unchecked. ( 25671134 )
2015
43
In vitro evaluation of curcumin effects on breast adenocarcinoma 2D and 3D cell cultures. ( 25826489 )
2015
44
Inhibition of the transient receptor potential melastatin-2 channel causes increased DNA damage and decreased proliferation in breast adenocarcinoma cells. ( 25760245 )
2015
45
Oseltamivir phosphate monotherapy ablates tumor neovascularization, growth, and metastasis in mouse model of human triple-negative breast adenocarcinoma. ( 25525387 )
2014
46
Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate. ( 24760710 )
2014
47
Lipid Peroxidation and Altered Anti-oxidant Status in Breast Adenocarcinoma Patients. ( 25050522 )
2014
48
Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain. ( 25349381 )
2014
49
Targeting of the I^6 gene to suppress degradation of ECM via inactivation of the MAPK pathway in breast adenocarcinoma cells. ( 25176506 )
2014
50
Raman spectroscopy of serum: A study on 'pre' and 'post' breast adenocarcinoma resection in rat models. ( 25044732 )
2014

Variations for Breast Adenocarcinoma

ClinVar genetic disease variations for Breast Adenocarcinoma:

6 (show all 11)
id Gene Variation Type Significance SNP ID Assembly Location
1 RB1CC1 NG_015833.1: g.34008_95699del61692 deletion Pathogenic GRCh38 Chromosome 8, 52623768: 52685459
2 RB1CC1 NG_015833.1: g.57807_94706del36900 deletion Pathogenic GRCh38 Chromosome 8, 52624761: 52661660
3 SLC22A18 NM_002555.5(SLC22A18): c.864_865insNC_000011.10: g.2919738_2919848 insertion Pathogenic
4 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
5 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
6 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
7 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
8 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
9 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
10 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
11 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551

Expression for Breast Adenocarcinoma

Search GEO for disease gene expression data for Breast Adenocarcinoma.

Pathways for Breast Adenocarcinoma

Pathways related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 121)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.15 CASP8 CDKN1A CTSK EGF EGFR ERBB2
2
Show member pathways
13.97 BAX CASP7 CASP8 CYCS EGF EGFR
3
Show member pathways
13.94 BAX CASP7 CASP8 CDKN1A CYCS EGF
4
Show member pathways
13.77 BAX CASP7 CASP8 CDKN1A EGF EGFR
5
Show member pathways
13.52 BAX CDKN1A EGF EGFR ERBB2 FOS
6
Show member pathways
13.48 CDKN1A EGF EGFR ERBB2 FOS MMP9
7
Show member pathways
13.42 BAX CASP7 CASP8 EGF EGFR ERBB2
8
Show member pathways
13.37 CASP8 EGF EGFR ERBB2 ESR1 FOS
9
Show member pathways
13.3 BAX CYCS EGF EGFR ERBB2 FOS
10
Show member pathways
13.02 CASP7 CASP8 CYCS EGFR FOS TNF
11
Show member pathways
13.01 BAX CDKN1A EGF EGFR ERBB2 ESR1
12
Show member pathways
13 BAX CASP8 CDKN1A CTSK CYCS FOS
13
Show member pathways
12.97 BAX CASP7 CASP8 CYCS MMP9 PARP1
14
Show member pathways
12.92 BAX CYCS ERBB2 ESR1 FOS PLAU
15
Show member pathways
12.89 CASP8 CYCS FOS TNF TP53
16
Show member pathways
12.88 CASP8 CYCS EGFR ESR1 FOS MMP9
17
Show member pathways
12.82 CDKN1A EGF EGFR ERBB2 TP53
18 12.81 CASP7 CASP8 EGF EGFR FOS TNF
19
Show member pathways
12.77 CASP8 CDKN1A ESR1 PARP1 TP53
20
Show member pathways
12.76 EGF EGFR FOS TNF TP53
21
Show member pathways
12.75 CASP7 CASP8 CYCS FOS TNF TNFSF11
22
Show member pathways
12.66 BAX CASP7 CDKN1A EGFR ERBB2 FOS
23 12.65 CDKN1A EGFR ERBB2 MMP9 PLAU TP53
24
Show member pathways
12.63 CASP7 CASP8 CYCS FOS PARP1 TNF
25
Show member pathways
12.61 CASP7 CASP8 EGF EGFR ERBB2 FOS
26
Show member pathways
12.6 BAX ERBB2 ESR1 FOS TNFSF11
27
Show member pathways
12.57 BAX CASP7 CASP8 EGFR ERBB2 TP53
28 12.55 BAX CDKN1A FOS TNF TP53
29
Show member pathways
12.5 BAX CASP8 CDKN1A CYCS TP53
30
Show member pathways
12.48 BAX CDKN1A FOS TP53
31
Show member pathways
12.42 CASP8 FOS MMP9 TNF
32
Show member pathways
12.42 CDKN1A EGF EGFR ERBB2 FOS TP53
33
Show member pathways
12.41 EGF EGFR ERBB2 ESR1
34 12.39 BAX CASP8 CDKN1A TP53
35
Show member pathways
12.37 BAX CASP7 CASP8 CYCS PARP1 TNF
36
Show member pathways
12.36 BAX CASP7 CASP8 CDKN1A FOS TP53
37
Show member pathways
12.36 BAX CASP7 CASP8 CDKN1A CTSK CYCS
38
Show member pathways
12.35 CASP7 FOS TNFSF11 TP53
39
Show member pathways
12.35 CASP8 CYCS FOS TNF
40 12.33 CDKN1A MMP9 PLAU TP53
41 12.32 BAX CASP8 CYCS TNF
42 12.29 BAX CASP8 EGFR ESR1 TP53
43 12.28 EGF EGFR ERBB2 FOS
44
Show member pathways
12.28 CDKN1A EGFR ERBB2 TP53
45 12.28 BAX CASP7 CASP8 CYCS NQO1 PARP1
46
Show member pathways
12.28 BAX CDKN1A CYCS EGF EGFR ERBB2
47
Show member pathways
12.24 EGF EGFR ERBB2 FOS
48
Show member pathways
12.23 CDKN1A EGF EGFR ERBB2 TP53
49
Show member pathways
12.22 CDKN1A EGF EGFR ERBB2
50 12.22 FOS MMP9 NQO1 TNF TP53

GO Terms for Breast Adenocarcinoma

Cellular components related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 ALDH3A1 CTSK EGF EGFR MMP9 PLAU

Biological processes related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 39)
id Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 9.97 BAX CASP8 ESR1 TP53
2 aging GO:0007568 9.93 ALDH3A1 CASP7 FOS NQO1
3 positive regulation of protein phosphorylation GO:0001934 9.91 EGFR ERBB2 MMP9 TNF
4 positive regulation of protein kinase B signaling GO:0051897 9.85 EGFR TNF TNFSF11
5 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.85 EGF EGFR ERBB2
6 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.85 BAX CASP8 TNF
7 phosphatidylinositol-mediated signaling GO:0048015 9.84 EGF EGFR ERBB2 TP53
8 apoptotic signaling pathway GO:0097190 9.83 BAX CASP8 TNF
9 response to glucocorticoid GO:0051384 9.83 ALDH3A1 CDKN1A TNF
10 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.81 BAX CDKN1A TP53
11 positive regulation of fibroblast proliferation GO:0048146 9.79 CDKN1A EGFR ESR1
12 positive regulation of neuron apoptotic process GO:0043525 9.79 BAX NQO1 TP53
13 response to toxic substance GO:0009636 9.78 BAX CDKN1A FOS NQO1
14 extrinsic apoptotic signaling pathway GO:0097191 9.76 BAX CASP8 TNF
15 response to estradiol GO:0032355 9.76 CASP8 EGFR ESR1 NQO1
16 ERBB2 signaling pathway GO:0038128 9.75 EGF EGFR ERBB2
17 response to gamma radiation GO:0010332 9.74 BAX PARP1 TP53
18 cellular response to reactive oxygen species GO:0034614 9.73 EGFR FOS MMP9
19 cellular response to cadmium ion GO:0071276 9.72 EGFR FOS MMP9
20 regulation of cell motility GO:2000145 9.7 EGF EGFR ERBB2
21 positive regulation of release of cytochrome c from mitochondria GO:0090200 9.69 BAX MMP9 TP53
22 replicative senescence GO:0090399 9.68 CDKN1A TP53
23 positive regulation of phosphorylation GO:0042327 9.67 EGF EGFR TNFSF11
24 positive regulation of catenin import into nucleus GO:0035413 9.66 EGF EGFR
25 positive regulation of programmed cell death GO:0043068 9.65 CDKN1A TNF
26 vagina development GO:0060068 9.65 BAX ESR1
27 response to organic cyclic compound GO:0014070 9.65 ALDH3A1 CDKN1A EGFR FOS NQO1
28 response to salt stress GO:0009651 9.64 BAX TNF
29 death-inducing signaling complex assembly GO:0071550 9.64 CASP8 TNF
30 positive regulation of osteoclast differentiation GO:0045672 9.61 FOS TNF TNFSF11
31 signal transduction by p53 class mediator GO:0072331 9.6 CDKN1A TP53
32 mammary gland alveolus development GO:0060749 9.58 EGF ESR1 TNFSF11
33 macrophage differentiation GO:0030225 9.54 CASP8 MMP9 PARP1
34 negative regulation of ERBB signaling pathway GO:1901185 9.5 EGF EGFR ERBB2
35 activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c GO:0008635 9.33 BAX CASP7 CYCS
36 intrinsic apoptotic signaling pathway GO:0097193 9.26 BAX CDKN1A CYCS TP53
37 positive regulation of MAP kinase activity GO:0043406 9.02 EGF EGFR ERBB2 TNF TNFSF11
38 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.17 EGFR ESR1 FOS PARP1 TNF TNFSF11
39 positive regulation of transcription, DNA-templated GO:0045893 10.07 EGF EGFR ESR1 FOS TNF TP53

Molecular functions related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.89 BAX EGFR ERBB2 FOS TP53
2 protein kinase binding GO:0019901 9.77 CDKN1A EGFR ESR1 PARP1 TP53
3 protein phosphatase binding GO:0019903 9.65 EGFR ERBB2 TP53
4 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.61 EGF EGFR ERBB2
5 cysteine-type endopeptidase activity GO:0004197 9.5 CASP7 CASP8 CTSK
6 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.46 EGFR ERBB2
7 cysteine-type endopeptidase activity involved in apoptotic process GO:0097153 9.4 CASP7 CASP8
8 identical protein binding GO:0042802 9.32 BAX CASP8 EGFR ERBB2 ESR1 MMP9
9 nitric-oxide synthase regulator activity GO:0030235 9.26 EGFR ESR1
10 tumor necrosis factor receptor binding GO:0005164 9.13 CASP8 TNF TNFSF11
11 protein binding GO:0005515 10.11 ALDH3A1 BAX CASP7 CASP8 CDKN1A CTSK

Sources for Breast Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....